NO20035173L - TACI-immunoglobulinfusjonsproteiner - Google Patents

TACI-immunoglobulinfusjonsproteiner

Info

Publication number: NO20035173L
Authority: NO; Norway
Prior art keywords: taci; ligand; immunoglobulinfusjonsproteiner; soluble; receptor
Prior art date: 2001-05-24

Application number

NO20035173A

Other languages

English (en)

Other versions

NO337295B1 (no

NO20035173D0 (no

Inventor

Jane A Gross

Mark W Rixon

Original Assignee

Zymogenetics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-24

Filing date

2003-11-21

Publication date

2004-01-23

2003-11-21 Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc

2003-11-21 Publication of NO20035173D0 publication Critical patent/NO20035173D0/no

2004-01-23 Publication of NO20035173L publication Critical patent/NO20035173L/no

2016-03-07 Publication of NO337295B1 publication Critical patent/NO337295B1/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Mycology (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Rheumatology (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Transplantation (AREA)

NO20035173A 2001-05-24 2003-11-21 TACI-immunglobulinfusjonsproteiner, nukleinsyremolekyl som koder for dem, fremgangsmåte for fremstilling av dem, anvendelse derav, og farmasøytisk preparat som omfatter dem og et farmasøytisk aksepterbart bærestoff. NO337295B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US29334301P	2001-05-24	2001-05-24
PCT/US2002/015910 WO2002094852A2 (en)	2001-05-24	2002-05-20	Taci-immunoglobulin fusion proteins

Publications (3)

Publication Number	Publication Date
NO20035173D0 NO20035173D0 (no)	2003-11-21
NO20035173L true NO20035173L (no)	2004-01-23
NO337295B1 NO337295B1 (no)	2016-03-07

Family

ID=23128690

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20035173A NO337295B1 (no)	2001-05-24	2003-11-21	TACI-immunglobulinfusjonsproteiner, nukleinsyremolekyl som koder for dem, fremgangsmåte for fremstilling av dem, anvendelse derav, og farmasøytisk preparat som omfatter dem og et farmasøytisk aksepterbart bærestoff.

Country Status (27)

Country	Link
US (9)	US20030103986A1 (no)
EP (2)	EP2116259B1 (no)
JP (2)	JP2004535182A (no)
KR (3)	KR100976743B1 (no)
CN (2)	CN101628111B (no)
AT (2)	ATE446771T1 (no)
AU (1)	AU2002305646C1 (no)
BR (1)	BRPI0209933B8 (no)
CA (1)	CA2448123C (no)
CY (2)	CY1109751T1 (no)
DE (1)	DE60234202D1 (no)
DK (2)	DK1436003T3 (no)
EA (2)	EA007275B1 (no)
ES (2)	ES2379977T3 (no)
HR (2)	HRP20130413A2 (no)
IL (2)	IL158920A0 (no)
ME (1)	MEP21708A (no)
MX (1)	MXPA03010687A (no)
NO (1)	NO337295B1 (no)
NZ (1)	NZ529638A (no)
PL (2)	PL403488A1 (no)
PT (2)	PT1436003E (no)
RS (2)	RS52228B (no)
SI (2)	SI1436003T1 (no)
UA (1)	UA82830C2 (no)
WO (1)	WO2002094852A2 (no)
ZA (1)	ZA200308984B (no)

Families Citing this family (207)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8212004B2 (en)	1999-03-02	2012-07-03	Human Genome Sciences, Inc.	Neutrokine-alpha fusion proteins
US6812327B1 (en)	1996-10-25	2004-11-02	Human Genome Sciences, Inc.	Neutrokine-alpha polypeptides
US7833529B1 (en)	1999-01-07	2010-11-16	Zymogenetics, Inc.	Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US6969519B2 (en)	2000-03-10	2005-11-29	Human Genome Sciences, Inc.	Methods of using an agonistic antibody human tumor necrosis factor receptor (TR17)
EP2275449B1 (en) *	2000-06-16	2016-09-28	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to BLyS
US7879328B2 (en)	2000-06-16	2011-02-01	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator
US20030091565A1 (en)	2000-08-18	2003-05-15	Beltzer James P.	Binding polypeptides and methods based thereon
ATE451390T1 (de)	2000-08-18	2009-12-15	Dyax Corp	Polypeptide zur bindung an das b-lymphozyten- stimulatorische protein (blys)
JP2004537290A (ja)	2001-05-24	2004-12-16	ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド	腫瘍壊死因子δ（ＡＰＲＩＬ）に対する抗体
DK1436003T3 (da) *	2001-05-24	2010-03-15	Zymogenetics Inc	TACI-immunoglobulin-fusionsproteiner
KR20040019105A (ko) *	2001-08-03	2004-03-04	제넨테크, 인크.	ＴＡＣＩｓ 및 ＢＲ3 폴리펩티드 및 이의 용도
US7112410B1 (en)	2001-08-29	2006-09-26	Human Genome Sciences, Inc.	Human tumor necrosis factor TR21 and methods based thereon
AU2002330074A1 (en) *	2001-09-21	2003-04-01	Amgen Inc.	Tall-1 receptor molecules and uses thereof
EP1495055B1 (en) *	2002-04-18	2013-08-14	Genencor International, Inc.	Production of functional antibodies in filamentous fungi
AU2003267967B2 (en) *	2002-06-18	2008-11-20	Zymogenetics, Inc.	Hybrid vector having a cytomegalovirus enhancer and myeloproliferative sarcoma virus promoter
DE60329116D1 (de) *	2002-10-11	2009-10-15	Zymogenetics Inc	Herstellung von homotrimeren fusionsproteinen
NZ583292A (en)	2003-11-06	2012-03-30	Seattle Genetics Inc	Monomethylvaline compounds capable of conjugation to ligands
US7381794B2 (en)	2004-03-08	2008-06-03	Zymogenetics, Inc.	Dimeric fusion proteins and materials and methods for producing them
MXPA06014065A (es)	2004-06-01	2007-01-31	Genentech Inc	Conjugados de droga-anticuerpo y metodos.
ES2551852T3 (es)	2004-07-23	2015-11-24	Acceleron Pharma Inc.	Polipéptidos del receptor ActRII
US20100111856A1 (en)	2004-09-23	2010-05-06	Herman Gill	Zirconium-radiolabeled, cysteine engineered antibody conjugates
ES2579805T3 (es)	2004-09-23	2016-08-16	Genentech, Inc.	Anticuerpos y conjugados modificados por ingeniería genética con cisteína
EP2083081A1 (en)	2005-07-22	2009-07-29	Five Prime Therapeutics, Inc.	Compositions and methods of treating disease with FGFR fusion proteins
AU2006278227B2 (en) *	2005-08-09	2011-10-20	Ares Trading S.A.	Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
ZA200801354B (en)	2005-08-09	2009-08-26	Ares Trading Sa	Methods for treating B-cell malignancies using TACI-lg fusion molecule
AU2006281978A1 (en) *	2005-08-12	2007-02-22	Garvan Institute Of Medical Research	Phrophylactic and/or therapeutic method for treatment of autoimmune disease
EA015860B1 (ru)	2005-10-13	2011-12-30	Хьюман Дженом Сайенсиз, Инк.	Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
US9168286B2 (en)	2005-10-13	2015-10-27	Human Genome Sciences, Inc.	Methods and compositions for use in treatment of patients with autoantibody positive disease
EA201692543A1 (ru)	2005-11-23	2017-08-31	Акселерон Фарма Инк.	Антагонисты активина-actriia и их применение для стимулирования роста кости
US8128933B2 (en)	2005-11-23	2012-03-06	Acceleron Pharma, Inc.	Method of promoting bone growth by an anti-activin B antibody
CA2629306A1 (en)	2005-11-23	2007-05-31	Genentech, Inc.	Methods and compositions related to b cell assays
JP2009525765A (ja) *	2006-02-10	2009-07-16	ザイモジェネティクス，インコーポレイテッド	切断型のｉｌ−１７ｒａ可溶性受容体および炎症において使用する方法
US8211649B2 (en)	2006-03-31	2012-07-03	Human Genome Sciences, Inc.	Methods of diagnosing and prognosing hodgkin's lymphoma
EA015342B1 (ru) *	2006-05-15	2011-06-30	Арес Трейдинг С.А.	Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig
WO2008025032A1 (en) *	2006-08-25	2008-02-28	Zymogenetics, Inc.	Soluble il-27 receptor
JP2010501622A (ja) *	2006-08-28	2010-01-21	アレストレーディングソシエテアノニム	Ｆｃ−融合タンパク質の精製法
BRPI0716139A2 (pt) *	2006-08-28	2013-09-17	Ares Trading Sa	processo para purificaÇço de proteÍnas de fusço fc
ES2755386T5 (es)	2006-08-28	2023-04-05	Ares Trading Sa	Proceso para la purificación de proteínas que contienen fragmentos Fc
ZA200900837B (en) *	2006-08-28	2010-05-26	Ares Trading Sa	Process for the purification of FC-containing proteins
EP2064234B1 (en) *	2006-09-18	2011-11-02	Compugen Ltd.	Bioactive peptides and method of using same
US8895016B2 (en)	2006-12-18	2014-11-25	Acceleron Pharma, Inc.	Antagonists of activin-actriia and uses for increasing red blood cell levels
US20100063257A1 (en) *	2007-01-26	2010-03-11	Merck Serono Sa	Purification of FC-TACI Fusion Proteins Using the Oilbody Technology
CA2677007A1 (en)	2007-02-01	2008-08-07	Acceleron Pharma Inc.	Activin-actriia antagonists and uses for treating or preventing breast cancer
TWI782836B (zh)	2007-02-02	2022-11-01	美商艾瑟勒朗法瑪公司	衍生自ActRIIB的變體與其用途
CA3039330C (en)	2007-02-09	2021-11-09	Acceleron Pharma Inc.	Activin-actriia antagonists and uses for promoting bone growth in cancer patients
CA2681917A1 (en) *	2007-03-27	2008-10-02	Christopher Hovens	Methods and compositions for treating prostate cancer
ES2422479T3 (es) *	2007-03-27	2013-09-11	Zymogenetics Inc	Combinación de inhibición de BLyS y micofenolato de mofetilo para tratamiento de enfermedades autoinmunitarias
CN101323643B (zh) *	2007-06-15	2010-12-01	烟台荣昌生物工程有限公司	优化的TACI-Fc融合蛋白
ES2537580T3 (es)	2007-09-04	2015-06-09	Compugen Ltd.	Polipéptidos y polinucleótidos, y usos de los mismos como una diana farmacológica para producir fármacos y agentes biológicos
CN103877564A (zh)	2007-09-18	2014-06-25	阿塞勒隆制药公司	活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
WO2009052293A1 (en) *	2007-10-16	2009-04-23	Zymogenetics, Inc.	Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
CN105168123B (zh)	2007-11-12	2019-03-08	阿雷斯贸易股份有限公司	Taci-免疫球蛋白融合蛋白制剂
EP2219673A1 (en) *	2007-11-12	2010-08-25	Ares Trading S.A.	Taci-immunoglobulin fusion proteins for treatment of relapsing multiple sclerosis
CA2703545A1 (en) *	2007-11-12	2009-05-22	Ares Trading S.A.	Taci-immunoglobulin fusion proteins for treatment of optic neuritis
JP5745274B2 (ja)	2007-12-07	2015-07-08	ザイモジェネティクス，インコーポレイテッド	抗ヒトｉｌ−２１モノクローナル抗体
EP2240196A2 (en) *	2008-01-22	2010-10-20	Compugen Ltd.	Clusterin derived peptide
EP2283355A2 (en) *	2008-04-25	2011-02-16	Zymogenetics, Inc.	Levels of bcma protein expression on b cells and use in diagnostic methods
US8003335B2 (en)	2008-04-30	2011-08-23	Universite Paris-SUD11	Levels of APRIL in serum and use in diagnostic methods
SI2291657T1 (sl)	2008-05-01	2016-09-30	Zymogenetics, Inc.	Nivoji blys/april heterotrimerjev v serumu in uporaba pri diagnostičnih postopkih
CN102131517B (zh)	2008-06-27	2014-12-17	津莫吉尼蒂克斯公司	可溶性杂合Fc γ受体和相关的方法
US8216997B2 (en)	2008-08-14	2012-07-10	Acceleron Pharma, Inc.	Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
JP5922928B2 (ja)	2008-08-14	2016-05-24	アクセルロンファーマ，インコーポレイテッド	赤血球レベルを高めるためのｇｄｆトラップの使用
EP2343080B1 (en) *	2008-09-30	2017-11-08	Kyowa Hakko Kirin Co., Ltd.	PHARMACEUTICAL COMPOSITION FOR TREATING BONE DISEASES WHICH COMPRISES PROTEIN COMPRISING Frizzled1, Frizzled2 OR Frizzled7 EXTRACELLULAR CYSTEINE-RICH DOMAIN AND Fc PROTEIN
WO2010067308A2 (en)	2008-12-08	2010-06-17	Compugen Ltd.	Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
WO2010096394A2 (en)	2009-02-17	2010-08-26	Redwood Biosciences, Inc.	Aldehyde-tagged protein-based drug carriers and methods of use
CN102548617B (zh)	2009-03-30	2017-11-07	阿塞勒隆制药公司	Bmp‑alk3拮抗剂和促进骨生长的用途
CN102482339B (zh)	2009-06-08	2015-06-17	阿塞勒隆制药公司	用于增加产热脂肪细胞的方法
EP2440577A4 (en)	2009-06-12	2013-01-23	Acceleron Pharma Inc	SHORTEN ACTRIIB FC FUSION PROTEINS
CA2809819A1 (en)	2009-09-09	2011-03-17	Centrose, Llc	Extracellular targeted drug conjugates
US8614183B2 (en)	2009-11-13	2013-12-24	Five Prime Therapeutics, Inc.	Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2
ES2658292T3 (es)	2009-11-17	2018-03-09	Acceleron Pharma, Inc.	Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
US9428586B2 (en)	2009-12-01	2016-08-30	Compugen Ltd	Heparanase splice variant
WO2011102845A1 (en) *	2010-02-18	2011-08-25	Transtech Pharma, Inc.	Rage fusion protein compositions and methods of use
WO2011109280A1 (en)	2010-03-05	2011-09-09	Lerner Research Institute	Methods and compositions to treat immune-mediated disorders
US10745467B2 (en)	2010-03-26	2020-08-18	The Trustees Of Dartmouth College	VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20150231215A1 (en)	2012-06-22	2015-08-20	Randolph J. Noelle	VISTA Antagonist and Methods of Use
CA2794483C (en)	2010-03-26	2020-07-07	Trustees Of Dartmouth College	Vista regulatory t cell mediator protein, vista binding agents and use thereof
US20110256157A1 (en)	2010-04-15	2011-10-20	Spirogen Limited	Pyrrolobenzodiazepines and conjugates thereof
CN101851278B (zh) *	2010-05-26	2013-03-13	石药集团中奇制药技术（石家庄）有限公司	B细胞激活因子拮抗剂及其制备方法与用途
JP2013534520A (ja)	2010-06-08	2013-09-05	ジェネンテック，インコーポレイテッド	システイン操作抗体及びコンジュゲート
US8822642B2 (en)	2010-06-09	2014-09-02	Zymogenetics, Inc.	Dimeric fusion proteins and related compositions and methods
EP3327035A1 (en)	2010-06-22	2018-05-30	Precision Biologics Inc.	Colon and pancreas cancer specific antigens and antibodies
CN107441480A (zh)	2010-06-30	2017-12-08	卡姆普根有限公司	多肽及其作为用于治疗多发性硬化、类风湿性关节炎以及其他自身免疫病症的药物的用途
WO2012040617A2 (en)	2010-09-23	2012-03-29	Neogenix Oncology, Inc.	Colon and pancreas cancer peptidomimetics
US20120258496A1 (en) *	2010-09-27	2012-10-11	Boehringer Ingelheim International Gmbh	Production of low fucose antibodies in h4-ii-e rat cells
CN103298832A (zh)	2010-11-08	2013-09-11	阿塞勒隆制药公司	Actriia结合剂及其用途
US8481038B2 (en)	2010-11-15	2013-07-09	Five Prime Therapeutics, Inc.	Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
ES2544608T3 (es)	2010-11-17	2015-09-02	Genentech, Inc.	Conjugados de anticuerpo y de alaninil-maitansinol
WO2012071561A2 (en)	2010-11-23	2012-05-31	Alder Biopharmaceuticals, Inc.	Anti-il-6 antibodies for the treatment of anemia
US8951972B2 (en)	2010-12-09	2015-02-10	Five Prime Therapeutics, Inc.	FGFR1 extracellular domain combination therapies for lung cancer
WO2012090150A2 (en)	2010-12-27	2012-07-05	Compugen Ltd	New cell-penetrating peptides and uses thereof
US9540438B2 (en)	2011-01-14	2017-01-10	Redwood Bioscience, Inc.	Aldehyde-tagged immunoglobulin polypeptides and methods of use thereof
CN102085367B (zh) *	2011-01-19	2012-08-22	烟台荣昌生物工程有限公司	优化的TACI-Fc融合蛋白用于制备治疗类风湿性关节炎药物的应用
US9409987B2 (en)	2011-04-15	2016-08-09	Compugen Ltd	Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
CA2833212C (en)	2011-05-12	2020-06-09	Genentech, Inc.	Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
US9067997B2 (en)	2011-05-25	2015-06-30	Innate Pharma Sa	Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders
EP2726503B1 (en)	2011-06-30	2019-09-04	Compugen Ltd.	Polypeptides and uses thereof for treatment of autoimmune disorders and infection
HRP20151374T1 (hr)	2011-10-14	2016-01-15	Medimmune Limited	Pirolobenzodiazepini i njihovi konjugati
CN107823630A (zh)	2011-11-14	2018-03-23	戊瑞治疗有限公司	治疗癌症的方法
KR20140126357A (ko)	2012-02-01	2014-10-30	컴퓨젠 엘티디.	C1orf32 항체 및 이의 암 치료를 위한 용도
WO2013130093A1 (en)	2012-03-02	2013-09-06	Genentech, Inc.	Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
TWI677507B (zh)	2012-06-22	2019-11-21	達特茅斯學院基金會	新穎之ｖｉｓｔａ－ｉｇ構築體及ｖｉｓｔａ－ｉｇ用於治療自體免疫、過敏及發炎病症之用途
US9890215B2 (en)	2012-06-22	2018-02-13	King's College London	Vista modulators for diagnosis and treatment of cancer
EP2892558B1 (en)	2012-09-07	2019-04-10	The Trustees Of Dartmouth College	Vista modulators for diagnosis and treatment of cancer
JP6392764B2 (ja)	2012-10-12	2018-09-19	エイディーシー・セラピューティクス・エス・アーＡｄｃＴｈｅｒａｐｅｕｔｉｃｓＳａ	ピロロベンゾジアゼピン−抗体結合体
HRP20182129T1 (hr)	2012-10-12	2019-02-08	Adc Therapeutics Sa	Konjugati protutijelo - pirolobenzodiazepin
JP6270859B2 (ja)	2012-10-12	2018-01-31	エイディーシー・セラピューティクス・エス・アー・エール・エルＡｄｃＴｈｅｒａｐｅｕｔｉｃｓＳａｒｌ	ピロロベンゾジアゼピン−抗体結合体
EP2906297B1 (en)	2012-10-12	2017-12-06	ADC Therapeutics SA	Pyrrolobenzodiazepine-antibody conjugates
HUE045435T2 (hu)	2012-10-12	2019-12-30	Medimmune Ltd	Pirrolobenzodiazepinek és konjugátumaik
LT2906251T (lt)	2012-10-12	2017-12-11	Adc Therapeutics Sa	Pirolobenzodiazepino-anti-cd22 antikūno konjugatai
EP2906250B1 (en)	2012-10-12	2018-05-30	ADC Therapeutics SA	Pyrrolobenzodiazepine-anti-psma antibody conjugates
MX366336B (es)	2012-11-02	2019-07-05	Celgene Corp	Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
CN103833856B (zh) *	2012-11-22	2017-05-03	上海康岱生物医药技术股份有限公司	抑制taci‑baff复合物形成的融合蛋白及其制法和用途
AU2013366493B2 (en)	2012-12-21	2017-08-24	Medimmune Limited	Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en)	2012-12-21	2017-02-14	Medimmune Limited	Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
CN105307685B (zh)	2013-03-13	2019-03-08	麦迪穆有限责任公司	吡咯并苯并二氮杂卓和其结合物
JP6444902B2 (ja)	2013-03-13	2018-12-26	メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅＬｉｍｉｔｅｄ	ピロロベンゾジアゼピン及びその結合体
CA2904044C (en)	2013-03-13	2020-03-31	Medimmune Limited	Pyrrolobenzodiazepines and conjugates thereof
MX2016001862A (es)	2013-08-12	2016-08-03	Genentech Inc	Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo[e]indol, y metodos de uso y tratamiento.
GB201317982D0 (en)	2013-10-11	2013-11-27	Spirogen Sarl	Pyrrolobenzodiazepines and conjugates thereof
US9956299B2 (en)	2013-10-11	2018-05-01	Medimmune Limited	Pyrrolobenzodiazepine—antibody conjugates
WO2015052532A1 (en)	2013-10-11	2015-04-16	Spirogen Sàrl	Pyrrolobenzodiazepine-antibody conjugates
US9950078B2 (en)	2013-10-11	2018-04-24	Medimmune Limited	Pyrrolobenzodiazepine-antibody conjugates
EP3082874A2 (en)	2013-12-16	2016-10-26	Genentech, Inc.	Peptidomimetic compounds and antibody-drug conjugates thereof
JP6980384B2 (ja)	2013-12-16	2021-12-15	ジェネンテック，インコーポレイテッド	１−（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
AU2014364927A1 (en)	2013-12-16	2016-07-07	Genentech, Inc.	Peptidomimetic compounds and antibody-drug conjugates thereof
CN119775416A (zh)	2013-12-24	2025-04-08	杨森制药公司	抗vista抗体及片段
US11014987B2 (en)	2013-12-24	2021-05-25	Janssen Pharmaceutics Nv	Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
JP6997619B2 (ja)	2014-06-11	2022-01-17	キャシー・エイ・グリーン	液性免疫の抑制または増進のための、ｖｉｓｔａアゴニスト及びｖｉｓｔａアンタゴニストの使用
AU2015274277B2 (en)	2014-06-13	2021-03-18	Acceleron Pharma, Inc.	Methods and compositions for treating ulcers
EP3185885B1 (en)	2014-08-26	2020-08-19	Compugen Ltd.	Polypeptides and uses thereof as a drug for treatment of autoimmune disorders
JP6531166B2 (ja)	2014-09-10	2019-06-12	メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅＬｉｍｉｔｅｄ	ピロロベンゾジアゼピン及びそのコンジュゲート
JP6622293B2 (ja)	2014-09-12	2019-12-18	ジェネンテック，インコーポレイテッド	アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法
AU2015314826A1 (en)	2014-09-12	2017-03-02	Genentech, Inc.	Cysteine engineered antibodies and conjugates
GB201416112D0 (en)	2014-09-12	2014-10-29	Medimmune Ltd	Pyrrolobenzodiazepines and conjugates thereof
CA2959689A1 (en)	2014-09-17	2016-03-24	Genentech, Inc.	Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
MA41052A (fr)	2014-10-09	2017-08-15	Celgene Corp	Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
US10676733B2 (en)	2014-10-28	2020-06-09	Merck Patent Gmbh	Methods for non-covalent Fc-domain-containing protein display on the surface of cells and methods of screening thereof
JP6734271B2 (ja)	2014-11-03	2020-08-05	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	二重特異性サメ抗体可変ドメインの製造方法およびそれらの使用
EP3223854A1 (en)	2014-11-25	2017-10-04	ADC Therapeutics SA	Pyrrolobenzodiazepine-antibody conjugates
KR20170086121A (ko)	2014-12-03	2017-07-25	제넨테크, 인크.	4급 아민 화합물 및 그의 항체-약물 접합체
SMT202300166T1 (it)	2014-12-03	2023-07-20	Celgene Corp	Antagonisti di attivina- actrii e usi per il trattamento di sindrome mielodisplastica
AU2015357463B2 (en)	2014-12-05	2021-10-07	Immunext, Inc.	Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
GB201506411D0 (en)	2015-04-15	2015-05-27	Bergenbio As	Humanized anti-axl antibodies
GB201506402D0 (en)	2015-04-15	2015-05-27	Berkel Patricius H C Van And Howard Philip W	Site-specific antibody-drug conjugates
EP3722314A1 (en)	2015-06-24	2020-10-14	Janssen Pharmaceutica NV	Anti-vista antibodies and fragments
ES2855998T3 (es)	2015-08-07	2021-09-27	Merck Patent Gmbh	Etiqueta transglutamina para bioconjugación específica de sitio eficiente
KR102440820B1 (ko)	2015-09-08	2022-09-05	테리피온, 인크.	ApoA-1 융합 폴리펩티드 및 관련 조성물 및 방법
MA43345A (fr)	2015-10-02	2018-08-08	Hoffmann La Roche	Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr)	2015-10-16	2018-08-22	Genentech Inc	Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr)	2015-10-20	2018-08-29	Genentech Inc	Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en)	2016-01-26	2016-03-09	Medimmune Ltd	Pyrrolobenzodiazepines
GB201602359D0 (en)	2016-02-10	2016-03-23	Medimmune Ltd	Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en)	2016-02-10	2016-03-23	Medimmune Ltd	Pyrrolobenzodiazepine Conjugates
MX2018009800A (es)	2016-02-12	2018-11-09	Janssen Pharmaceutica Nv	Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos.
EP3433621A1 (en)	2016-03-25	2019-01-30	H. Hoffnabb-La Roche Ag	Multiplexed total antibody and antibody-conjugated drug quantification assay
EP3448412A4 (en)	2016-04-15	2020-03-25	Immunext Inc.	ANTI-HUMAN-VISTA ANTIBODIES AND USE THEREOF
JP2019515671A (ja)	2016-04-15	2019-06-13	アルダーバイオファーマシューティカルズ、インコーポレイテッド	抗ｐａｃａｐ抗体及びそれらの使用
JP2019515677A (ja)	2016-04-26	2019-06-13	アール．ピー．シェーラーテクノロジーズエルエルシー	抗体複合体ならびにそれを作製および使用する方法
GB201607478D0 (en)	2016-04-29	2016-06-15	Medimmune Ltd	Pyrrolobenzodiazepine Conjugates
PL3458101T3 (pl)	2016-05-20	2021-05-31	F. Hoffmann-La Roche Ag	Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
WO2017205741A1 (en)	2016-05-27	2017-11-30	Genentech, Inc.	Bioanalytical method for the characterization of site-specific antibody-drug conjugates
CN109476648B (zh)	2016-06-06	2022-09-13	豪夫迈·罗氏有限公司	司维司群抗体-药物缀合物和使用方法
WO2018027042A1 (en)	2016-08-03	2018-02-08	Bio-Techne Corporation	Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy
EP3496763A1 (en)	2016-08-11	2019-06-19	Genentech, Inc.	Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
EP3522933B1 (en)	2016-10-05	2021-12-15	F. Hoffmann-La Roche AG	Methods for preparing antibody drug conjugates
GB201617466D0 (en)	2016-10-14	2016-11-30	Medimmune Ltd	Pyrrolobenzodiazepine conjugates
WO2018136163A2 (en)	2016-12-09	2018-07-26	Theripion, Inc.	Tandem apoa-1 fusion polypeptides
KR20200032243A (ko)	2017-02-08	2020-03-25	에이디씨 테라퓨틱스 에스에이	피롤로벤조디아제핀-항체 컨주게이트
GB201702031D0 (en)	2017-02-08	2017-03-22	Medlmmune Ltd	Pyrrolobenzodiazepine-antibody conjugates
SI3612537T1 (sl)	2017-04-18	2022-10-28	Medimmune Limited	Konjugati pirolobenzodiazepina
EP3612234B1 (en)	2017-04-20	2024-03-13	ADC Therapeutics SA	Combination therapy with an anti-axl antibody-drug conjugate
JP7265788B2 (ja)	2017-05-09	2023-04-27	シアノバイオテックゲーエムベーハー	修飾ミクロシスチンおよびノジュラリン
IL270522B2 (en)	2017-05-09	2024-04-01	Simris Biologics Gmbh	Method for modifying microcystins and nodularins
KR102442736B1 (ko)	2017-06-14	2022-09-16	에이디씨 테라퓨틱스 에스에이	항-cd19 adc의 투여를 위한 투약량 체제
CN111065638B (zh)	2017-08-18	2021-04-09	麦迪穆有限责任公司	吡咯并苯并二氮杂䓬缀合物
WO2019046818A1 (en) *	2017-09-01	2019-03-07	Dana-Farber Cancer Institute, Inc.	SPECIFIC IMMUNOGENIC PEPTIDES OF BCMA AND TACI ANTIGENS FOR THE TREATMENT OF CANCER
CN111788208B (zh)	2017-09-20	2023-11-24	Ph制药有限公司	泰兰他汀类似物
WO2019152810A1 (en)	2018-02-02	2019-08-08	Bio-Techne Corporation	Compounds that modulate the interaction of vista and vsig3 and methods of making and using
GB201803342D0 (en)	2018-03-01	2018-04-18	Medimmune Ltd	Methods
GB201806022D0 (en)	2018-04-12	2018-05-30	Medimmune Ltd	Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en)	2018-09-03	2018-10-17	Femtogenix Ltd	Cytotoxic agents
AU2019365238A1 (en)	2018-10-24	2021-05-13	F. Hoffmann-La Roche Ag	Conjugated chemical inducers of degradation and methods of use
WO2020123275A1 (en)	2018-12-10	2020-06-18	Genentech, Inc.	Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en)	2019-01-29	2019-03-20	Femtogenix Ltd	G-A Crosslinking cytotoxic agents
IL286326B2 (en)	2019-03-15	2025-10-01	Medimmune Ltd	Azatidobenzodiazepine dimers and conjugates containing them for use in the treatment of cancer
BR112021005478A2 (pt)	2019-07-24	2021-06-15	H. Lundbeck A/S	anticorpos anti-mglur5 e uso dos mesmos
US20220002381A1 (en) *	2019-12-24	2022-01-06	Remegen Co., Ltd.	Taci-fc fusion proteins and uses thereof
CN115812077A (zh)	2020-05-08	2023-03-17	高山免疫科学股份有限公司	April和baff抑制性免疫调节蛋白及其使用方法
PH12022553243A1 (en)	2020-06-02	2024-02-12	Ares Trading Sa	Methods related to the treatment of iga nephropathy
GB2597532A (en)	2020-07-28	2022-02-02	Femtogenix Ltd	Cytotoxic compounds
US12180521B2 (en)	2021-02-19	2024-12-31	Theripion, Inc.	Paraoxonase fusion polypeptides and related compositions and methods
BR112023022133A2 (pt)	2021-05-07	2023-12-26	Viela Bio Inc	Uso de um anticorpo anti-cd19 para tratar miastenia gravis
WO2022236335A1 (en)	2021-05-07	2022-11-10	Alpine Immune Sciences, Inc.	Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
US20240400670A1 (en) *	2021-09-30	2024-12-05	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Anti-il23 antibody fusion protein and uses thereof
EP4296287A4 (en) *	2021-09-30	2025-01-15	RemeGen Co., Ltd.	METHODS FOR TREATING SJÖGREN'S SYNDROME WITH TACI-FC FUSION PROTEIN
CA3236930A1 (en)	2021-11-03	2022-04-21	Hangzhou Dac Biotech Co., Ltd.	Specific conjugation of an antibody
WO2023236967A1 (zh) *	2022-06-08	2023-12-14	荣昌生物制药(烟台)股份有限公司	用TACI-Fc融合蛋白治疗重症肌无力的方法
TW202421653A (zh) *	2022-09-30	2024-06-01	大陸商榮昌生物製藥（煙臺）股份有限公司	用TACI-Fc融合蛋白治療膜性腎病的方法
EP4598557A2 (en)	2022-10-04	2025-08-13	Alpine Immune Sciences, Inc.	Mutated taci-fc fusion proteins for use in the treatment of autoantibody-mediated diseases
WO2024114777A1 (zh) *	2022-12-02	2024-06-06	荣昌生物制药(烟台)股份有限公司	用TACI-Fc融合蛋白治疗微小病变型肾病的方法
AU2023391468A1 (en) *	2022-12-05	2025-07-17	Alexion Pharmaceuticals, Inc.	Taci-fc fusion proteins for multifunctional inhibition of baff, april, and neonatal fc receptor
TW202432187A (zh)	2022-12-23	2024-08-16	美商建南德克公司	小腦蛋白降解劑結合物及其用途
WO2024197157A1 (en)	2023-03-21	2024-09-26	Biograph 55, Inc.	Cd19/cd38 multispecific antibodies
AU2024257248A1 (en)	2023-04-17	2025-11-06	Peak Bio, Inc.	Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
WO2024259220A1 (en)	2023-06-15	2024-12-19	Theripion, Inc.	Pon3 and evolved pon1 fusion polypeptides
WO2025007943A1 (zh) *	2023-07-06	2025-01-09	荣昌生物制药(烟台)股份有限公司	用taci-fc融合蛋白治疗anca相关性血管炎的方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5738A (en)		1848-08-29		Francis kelsey
US846A (en)		1838-07-17		Improvement in revolving fire-arms
DK368882A (da)	1981-08-25	1983-02-26	Alan John Kingsman	Expessions vektorer
US4769331A (en)	1981-09-16	1988-09-06	University Patents, Inc.	Recombinant methods and materials
US4486533A (en)	1982-09-02	1984-12-04	St. Louis University	Filamentous fungi functional replicating extrachromosomal element
US4599311A (en)	1982-08-13	1986-07-08	Kawasaki Glenn H	Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en)	1985-06-26	1990-12-11	Amgen	Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4603044A (en)	1983-01-06	1986-07-29	Technology Unlimited, Inc.	Hepatocyte Directed Vesicle delivery system
US5139936A (en)	1983-02-28	1992-08-18	Collaborative Research, Inc.	Use of the GAL1 yeast promoter
US4661454A (en)	1983-02-28	1987-04-28	Collaborative Research, Inc.	GAL1 yeast promoter linked to non galactokinase gene
US4870008A (en)	1983-08-12	1989-09-26	Chiron Corporation	Secretory expression in eukaryotes
EP0154316B1 (en)	1984-03-06	1989-09-13	Takeda Chemical Industries, Ltd.	Chemically modified lymphokine and production thereof
US4931373A (en)	1984-05-25	1990-06-05	Zymogenetics, Inc.	Stable DNA constructs for expression of α-1 antitrypsin
US5288641A (en)	1984-06-04	1994-02-22	Arch Development Corporation	Herpes Simplex virus as a vector
US4859587A (en)	1984-06-04	1989-08-22	Institut Merieux	Recombinant herpes simplex viruses, vaccines and methods
US4766073A (en)	1985-02-25	1988-08-23	Zymogenetics Inc.	Expression of biologically active PDGF analogs in eucaryotic cells
EP0184576B1 (en)	1984-12-06	1990-06-27	Fina Research S.A.	Promoters for the expression of foreign genes in yeast, plasmids comprising them, and uses thereof for the production of polypeptides
US4751181A (en)	1984-12-31	1988-06-14	Duke University	Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
US4882279A (en)	1985-10-25	1989-11-21	Phillips Petroleum Company	Site selective genomic modification of yeast of the genus pichia
US4935349A (en)	1986-01-17	1990-06-19	Zymogenetics, Inc.	Expression of higher eucaryotic genes in aspergillus
US5063154A (en)	1987-06-24	1991-11-05	Whitehead Institute For Biomedical Research	Pheromone - inducible yeast promoter
US5037743A (en)	1988-08-05	1991-08-06	Zymogenetics, Inc.	BAR1 secretion signal
US5162228A (en)	1988-12-28	1992-11-10	Takeda Chemical Industries, Ltd.	Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5399346A (en)	1989-06-14	1995-03-21	The United States Of America As Represented By The Department Of Health And Human Services	Gene therapy
US5328688A (en)	1990-09-10	1994-07-12	Arch Development Corporation	Recombinant herpes simplex viruses vaccines and methods
US5252714A (en)	1990-11-28	1993-10-12	The University Of Alabama In Huntsville	Preparation and use of polyethylene glycol propionaldehyde
JP3202999B2 (ja)	1991-01-31	2001-08-27	協和醗酵工業株式会社	肝移行性リポソーム製剤
US5298418A (en)	1991-09-16	1994-03-29	Boyce Thompson Institute For Plant Research, Inc.	Cell line isolated from larval midgut tissue of Trichoplusia ni
US5861151A (en) *	1991-12-20	1999-01-19	Bristol-Myers Squibb Co	Soluble fusion molecules with binding specificity for cell adhesion molecules
ZA932523B (en) *	1992-04-10	1994-10-08	Res Dev Foundation	Immunotoxins directed against cd33 related surface antigens
ZA932522B (en) *	1992-04-10	1993-12-20	Res Dev Foundation	Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5382657A (en)	1992-08-26	1995-01-17	Hoffmann-La Roche Inc.	Peg-interferon conjugates
WO1994009137A1 (en)	1992-10-15	1994-04-28	Genentech, Inc.	Antibodies against type 2 tumor necrosis factor receptor
US5650550A (en)	1993-10-01	1997-07-22	The United States Of America As Represented By The Department Of Health And Human Services	Mutant mice having a deficit of functional estrogen receptors
US5523227A (en)	1994-06-17	1996-06-04	The Board Of Trustees Of The Leland Stanford Junior Univ.	DNA encoding calcium-signal modulating cyclophilin ligand
JP3787355B2 (ja)	1994-12-15	2006-06-21	イエダリサーチアンドディベロップメントカンパニーリミテッド	Ｆａｓ／ａｐｏ１受容体機能のモジュレーター
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5739277A (en)	1995-04-14	1998-04-14	Genentech Inc.	Altered polypeptides with increased half-life
DE19533447C1 (de)	1995-09-09	1996-12-05	Bbs Kraftfahrzeugtechnik	Verfahren und Vorrichtung zum Befüllen eines Gießwerkzeugs mit einer Metallschmelze
US5716808A (en)	1995-11-09	1998-02-10	Zymogenetics, Inc.	Genetic engineering of pichia methanolica
WO1997017451A2 (en)	1995-11-09	1997-05-15	Zymogenetics, Inc.	Production of gad65 in methylotrophic yeast
AU726486C (en)	1996-03-14	2004-02-05	Human Genome Sciences, Inc.	Human tumor necrosis factor delta and epsilon
AU718510B2 (en)	1996-07-17	2000-04-13	Zymogenetics Inc.	Transformation of pichia methanolica
US5736383A (en)	1996-08-26	1998-04-07	Zymogenetics, Inc.	Preparation of Pichia methanolica auxotrophic mutants
JP2002514049A (ja)	1996-07-17	2002-05-14	ザイモジェネティクス，インコーポレイティド	ピヒア・メタノリカの栄養要求性突然変異体の製造
BR9612752A (pt)	1996-10-25	2000-01-18	Human Genome Sciences Inc	Neutrocina
WO1998027114A2 (en)	1996-12-17	1998-06-25	Schering Corporation	Mammalian cell surface antigens; related reagents
US5969102A (en)	1997-03-03	1999-10-19	St. Jude Children's Research Hospital	Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en)	1997-04-02	1998-10-02	Smithkline Beecham Corporation	A tnf homologue, tl5
TR199902878T2 (xx) *	1997-04-18	2000-02-21	Biogen,Inc.	Tip II TGF-Beta Resept�r/�m�noglob�lin sabit b�l�m f�zyon proteinleri.
AU743490B2 (en)	1997-06-06	2002-01-24	Regeneron Pharmaceuticals, Inc.	NTN-2 member of TNF ligand family
WO1998055621A1 (en)	1997-06-06	1998-12-10	Regeneron Pharmaceuticals, Inc.	Ntn-2 member of tnf ligand family
AU9013998A (en) *	1997-07-21	1999-02-10	Zymogenetics Inc.	Tumor necrosis factor receptor ztnfr-5
AU9376498A (en)	1997-09-05	1999-03-22	University Of Washington	Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
EA005411B1 (ru)	1997-09-12	2005-02-24	Апотек Р Энд Д Са	Применение антитела против полипептида april для получения лекарственного препарата для лечения опухолей
US20060067933A1 (en)	1999-01-07	2006-03-30	Gross Jane A	Soluble receptor BR43x2 and methods of using
DE60005135T3 (de) *	1999-01-07	2015-04-09	Zymogenetics, Inc.	Lösliche rezeptoren br43x2 und verfahren zu deren therapeutischen verwendung
CA2360062A1 (en)	1999-01-25	2000-07-27	Biogen, Inc.	Baff, inhibitors thereof and their use in the modulation of b-cell response
WO2000062790A2 (en)	1999-04-19	2000-10-26	Immunex Corporation	Soluble tumor necrosis factor receptor treatment of medical disorders
US20030022233A1 (en)	1999-04-30	2003-01-30	Raymond G. Goodwin	Methods of use of the taci/taci-l interaction
SK782002A3 (en) *	1999-07-21	2003-08-05	Lexigen Pharm Corp	FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
EP1210425B2 (en)	1999-08-17	2015-06-17	Biogen MA Inc.	Baff receptor (bcma), an immunoregulatory agent
AU7602400A (en) *	1999-09-20	2001-04-24	Millennium Pharmaceuticals, Inc.	Secreted proteins and uses thereof
UA74798C2 (uk)	1999-10-06	2006-02-15	Байоджен Айдек Ма Інк.	Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
PT1255558E (pt)	2000-02-16	2006-11-30	Genentech Inc	Anticorpos anti-april e células hibridoma
DK1272647T3 (en)	2000-04-11	2014-12-15	Genentech Inc	Multivalent antibodies and uses thereof
CA2404945C (en) *	2000-04-27	2010-02-09	Biogen, Inc.	Taci as an anti-tumor agent
CA2408617A1 (en) *	2000-05-12	2001-11-22	Amgen Inc.	Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
ES2344679T3 (es)	2000-08-11	2010-09-03	Kyowa Hakko Kirin Co., Ltd.	Polipeptidos que controlan el metabolismo del acido fosforico, el metabolismo del calcio, el metabolismo de la calcificacion y de la vitamina d y moleculas de adn que los codifican.
ATE432986T1 (de) *	2000-11-07	2009-06-15	Zymogenetics Inc	Menschlicher rezeptor für tumor necrosis factor
WO2002066516A2 (en)	2001-02-20	2002-08-29	Zymogenetics, Inc.	Antibodies that bind both bcma and taci
DK1436003T3 (da)	2001-05-24	2010-03-15	Zymogenetics Inc	TACI-immunoglobulin-fusionsproteiner
CN105168123B (zh)	2007-11-12	2019-03-08	阿雷斯贸易股份有限公司	Taci-免疫球蛋白融合蛋白制剂

2002
- 2002-05-20 DK DK02734478.7T patent/DK1436003T3/da active
- 2002-05-20 KR KR1020097013141A patent/KR100976743B1/ko not_active Expired - Lifetime
- 2002-05-20 WO PCT/US2002/015910 patent/WO2002094852A2/en not_active Ceased
- 2002-05-20 EP EP09168970A patent/EP2116259B1/en not_active Expired - Lifetime
- 2002-05-20 CA CA2448123A patent/CA2448123C/en not_active Expired - Lifetime
- 2002-05-20 EP EP02734478A patent/EP1436003B3/en not_active Expired - Lifetime
- 2002-05-20 EA EA200301146A patent/EA007275B1/ru not_active IP Right Cessation
- 2002-05-20 RS YU92503A patent/RS52228B/sr unknown
- 2002-05-20 CN CN200910146212XA patent/CN101628111B/zh not_active Expired - Lifetime
- 2002-05-20 ES ES09168970T patent/ES2379977T3/es not_active Expired - Lifetime
- 2002-05-20 JP JP2002592326A patent/JP2004535182A/ja not_active Withdrawn
- 2002-05-20 KR KR10-2003-7015353A patent/KR20040030628A/ko not_active Ceased
- 2002-05-20 ME MEP-217/08A patent/MEP21708A/xx unknown
- 2002-05-20 MX MXPA03010687A patent/MXPA03010687A/es active IP Right Grant
- 2002-05-20 PL PL403488A patent/PL403488A1/pl not_active Application Discontinuation
- 2002-05-20 UA UA20031110605A patent/UA82830C2/uk unknown
- 2002-05-20 SI SI200230868T patent/SI1436003T1/sl unknown
- 2002-05-20 ES ES02734478T patent/ES2334772T7/es active Active
- 2002-05-20 PT PT02734478T patent/PT1436003E/pt unknown
- 2002-05-20 AT AT02734478T patent/ATE446771T1/de active
- 2002-05-20 PL PL366760A patent/PL219013B1/pl not_active IP Right Cessation
- 2002-05-20 DK DK09168970.3T patent/DK2116259T3/da active
- 2002-05-20 BR BR0209933-0 patent/BRPI0209933B8/pt not_active IP Right Cessation
- 2002-05-20 SI SI200230979T patent/SI2116259T1/sl unknown
- 2002-05-20 CN CN02812698XA patent/CN1612750B/zh not_active Expired - Lifetime
- 2002-05-20 RS RS20120253A patent/RS20120253A1/sr unknown
- 2002-05-20 EA EA200600894A patent/EA010594B1/ru not_active IP Right Cessation
- 2002-05-20 AT AT09168970T patent/ATE542545T1/de active
- 2002-05-20 AU AU2002305646A patent/AU2002305646C1/en not_active Expired
- 2002-05-20 US US10/152,363 patent/US20030103986A1/en not_active Abandoned
- 2002-05-20 PT PT09168970T patent/PT2116259E/pt unknown
- 2002-05-20 KR KR1020107010485A patent/KR101021124B1/ko not_active Expired - Lifetime
- 2002-05-20 NZ NZ529638A patent/NZ529638A/en not_active IP Right Cessation
- 2002-05-20 HR HRP20130413AA patent/HRP20130413A2/hr not_active Application Discontinuation
- 2002-05-20 HR HRP20030948AA patent/HRP20030948B1/hr not_active IP Right Cessation
- 2002-05-20 DE DE60234202T patent/DE60234202D1/de not_active Expired - Lifetime
- 2002-05-20 IL IL15892002A patent/IL158920A0/xx active IP Right Grant
2003
- 2003-11-19 ZA ZA200308984A patent/ZA200308984B/en unknown
- 2003-11-21 NO NO20035173A patent/NO337295B1/no not_active IP Right Cessation
2005
- 2005-10-03 US US11/242,294 patent/US7501497B2/en not_active Expired - Lifetime
2009
- 2009-01-26 US US12/359,801 patent/US7635767B2/en not_active Expired - Lifetime
- 2009-06-22 JP JP2009147774A patent/JP5149245B2/ja not_active Expired - Lifetime
- 2009-10-26 US US12/605,561 patent/US7964711B2/en not_active Expired - Fee Related
- 2009-11-04 US US12/612,288 patent/US7951919B2/en not_active Expired - Fee Related
- 2009-11-05 US US12/613,039 patent/US7862814B2/en not_active Expired - Fee Related
2010
- 2010-01-27 CY CY20101100079T patent/CY1109751T1/el unknown
2011
- 2011-05-11 US US13/105,182 patent/US8524232B2/en not_active Expired - Fee Related
- 2011-12-29 IL IL217265A patent/IL217265A/en active IP Right Grant
2012
- 2012-04-24 CY CY20121100381T patent/CY1112840T1/el unknown
2013
- 2013-08-01 US US13/956,499 patent/US8815238B2/en not_active Expired - Lifetime
2014
- 2014-07-15 US US14/331,567 patent/US9346878B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
KR20040030628A (ko)	2004-04-09
JP2004535182A (ja)	2004-11-25
HK1137659A1 (en)	2010-08-06
WO2002094852A8 (en)	2004-04-22
HRP20030948B1 (hr)	2013-06-30
US8524232B2 (en)	2013-09-03
IL217265A0 (en)	2012-02-29
ZA200308984B (en)	2004-07-20
ES2379977T3 (es)	2012-05-07
US20140328844A1 (en)	2014-11-06
JP2009232856A (ja)	2009-10-15
PT1436003E (pt)	2010-03-12
ATE446771T1 (de)	2009-11-15
US20110229473A1 (en)	2011-09-22
PL219013B1 (pl)	2015-02-27
EP2116259A1 (en)	2009-11-11
US9346878B2 (en)	2016-05-24
PT2116259E (pt)	2012-04-09
UA82830C2 (en)	2008-05-26
CY1109751T1 (el)	2014-09-10
PL366760A1 (en)	2005-02-07
NO337295B1 (no)	2016-03-07
YU92503A (sh)	2006-05-25
US20090209006A1 (en)	2009-08-20
MXPA03010687A (es)	2004-07-01
CN1612750B (zh)	2012-10-31
EP1436003B3 (en)	2012-03-14
EA010594B1 (ru)	2008-10-30
CN101628111A (zh)	2010-01-20
JP5149245B2 (ja)	2013-02-20
SI2116259T1 (sl)	2012-11-30
DE60234202D1 (de)	2009-12-10
KR20100061860A (ko)	2010-06-09
PL403488A1 (pl)	2013-07-08
KR100976743B1 (ko)	2010-08-19
HRP20130413A2 (hr)	2013-07-31
US7964711B2 (en)	2011-06-21
CY1112840T1 (el)	2016-02-10
US7501497B2 (en)	2009-03-10
HRP20030948A2 (en)	2004-06-30
US7862814B2 (en)	2011-01-04
US20100130728A1 (en)	2010-05-27
IL158920A0 (en)	2004-05-12
CA2448123A1 (en)	2002-11-28
AU2002305646C1 (en)	2009-08-06
US20030103986A1 (en)	2003-06-05
RS52228B (sr)	2012-10-31
AU2002305646B2 (en)	2008-09-04
US20100129384A1 (en)	2010-05-27
SI1436003T1 (sl)	2010-02-26
BRPI0209933B1 (pt)	2018-10-16
DK2116259T3 (da)	2012-05-21
US20060034852A1 (en)	2006-02-16
CA2448123C (en)	2012-09-11
EA007275B1 (ru)	2006-08-25
NZ529638A (en)	2007-08-31
US7635767B2 (en)	2009-12-22
US20130309231A1 (en)	2013-11-21
EP1436003A2 (en)	2004-07-14
RS20120253A1 (sr)	2013-02-28
CN101628111B (zh)	2013-11-06
DK1436003T3 (da)	2010-03-15
MEP21708A (en)	2010-06-10
EP2116259B1 (en)	2012-01-25
WO2002094852A2 (en)	2002-11-28
ES2334772T7 (es)	2012-11-19
US8815238B2 (en)	2014-08-26
EP1436003B1 (en)	2009-10-28
EA200301146A2 (ru)	2004-06-24
US7951919B2 (en)	2011-05-31
ES2334772T3 (es)	2010-03-16
KR101021124B1 (ko)	2011-03-14
ATE542545T1 (de)	2012-02-15
US20100183609A1 (en)	2010-07-22
KR20090080570A (ko)	2009-07-24
IL217265A (en)	2013-05-30
EA200600894A1 (ru)	2007-08-31
EA200301146A3 (ru)	2005-02-24
BR0209933A (pt)	2004-03-30
NO20035173D0 (no)	2003-11-21
EP1436003A4 (en)	2005-04-27
BRPI0209933B8 (pt)	2021-05-25
HK1076603A1 (en)	2006-01-20
CN1612750A (zh)	2005-05-04

Publication	Publication Date	Title
NO20035173D0 (no)	2003-11-21	TACI-immunoglobulinfusjonsproteiner
WO2002066516A3 (en)	2003-03-06	Antibodies that bind both bcma and taci
WO2005077981A3 (en)	2006-02-16	Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
NO20074331L (no)	2007-10-17	Kromatografiske medier
CY1119291T1 (el)	2018-02-14	Πολυσθενη αντισωματα και χρησεις για αυτα
DK1328297T3 (da)	2010-02-01	Funktionen af en haptoglobin-hæmoglobin receptor og anvendelser heraf
ATE432986T1 (de)	2009-06-15	Menschlicher rezeptor für tumor necrosis factor
CR10147A (es)	2008-10-29	"ligandos que tienen especificidad de enlace para vegf y/o egfr y métodos de uso de los mismos"
CY1114032T1 (el)	2016-07-27	Χρηση πεπτιδιων που δεσμευουν τον τρο υποδοχεα
EA200600477A1 (ru)	2007-02-27	Пептиды и соединения, которые связываются с рецептором
DK1622929T3 (da)	2007-02-19	Apo-2L (TRAIL) receptorbindingspeptider og anvendelser deraf

Legal Events

Date	Code	Title	Description
2022-06-13	MK1K	Patent expired